» Articles » PMID: 3041218

Mutational Activation of the K-ras Oncogene. A Possible Pathogenetic Factor in Adenocarcinoma of the Lung

Overview
Journal N Engl J Med
Specialty General Medicine
Date 1987 Oct 8
PMID 3041218
Citations 161
Authors
Affiliations
Soon will be listed here.
Abstract

To define the role of cellular oncogenes in human cancers, we studied the prevalence of mutational activation of ras oncogenes in untreated non-small-cell lung cancer. Genomic DNA was extracted from 39 tumor specimens obtained by thoracotomy and was examined for activating point mutations in codons 12, 13, and 61 of the H-ras, K-ras, and N-ras genes. A novel, highly sensitive assay based on oligonucleotide hybridization following an in vitro amplification step was employed. The K-ras gene was found to be activated by point mutations in codon 12 in 5 of 10 adenocarcinomas. Two of these tumors were less than 2 cm in size and had not metastasized. No ras gene mutations were observed in 15 squamous-cell carcinomas, 10 large-cell carcinomas, 1 carcinoid, 2 metastatic adenocarcinomas from primary tumors outside the lung, and 1 small-cell carcinoma. An approximately 20-fold amplification of the unmutated K-ras gene was observed in a tumor that proved to be a solitary lung metastasis of a rectal carcinoma. We conclude that mutational K-ras activation may be an important early event in the pathogenesis of adenocarcinoma of the lung but that amplification of ras genes or mutational activation of H-ras or N-ras does not play a major part in non-small-cell lung cancer.

Citing Articles

Clinical Advances and Challenges in Targeting KRAS Mutations in Non-Small Cell Lung Cancer.

Dekker S, Deng L Cancers (Basel). 2024; 16(22).

PMID: 39594840 PMC: 11593150. DOI: 10.3390/cancers16223885.


Dysregulation of the DRAIC/SBK1 Axis Promotes Lung Cancer Progression.

Alhammad R, Allison M, Alhammad F, Anene C Diagnostics (Basel). 2024; 14(19).

PMID: 39410631 PMC: 11475998. DOI: 10.3390/diagnostics14192227.


An updated overview of K-RAS G12C inhibitors in advanced stage non-small cell lung cancer.

Tenekeci A, Unal A, Ceylan F, Sendur M Future Oncol. 2024; 20(37):3019-3038.

PMID: 39360933 PMC: 11572139. DOI: 10.1080/14796694.2024.2407280.


Orthotopic Models Using New, Murine Lung Adenocarcinoma Cell Lines Simulate Human Non-Small Cell Lung Cancer Treated with Immunotherapy.

Knott E, Kim E, Kim E, Freire R, Medina J, Wang Y Cells. 2024; 13(13.

PMID: 38994972 PMC: 11240577. DOI: 10.3390/cells13131120.


Genomic Landscape of NSCLC in the Republic of Ireland.

Keogh R, Barr M, Keogh A, McMahon D, OBrien C, Finn S JTO Clin Res Rep. 2024; 5(2):100627.

PMID: 38333230 PMC: 10850121. DOI: 10.1016/j.jtocrr.2023.100627.